Patent ID: 11872230
Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating cancer or reducing the risk of recurrence of cancer in a subject; the method comprising the steps of:
a) detecting increased expression levels of methionine adenosyltransferase 2A (MAT2A), methylthioadenosine phosphorylase (MTAP) and cluster of differentiation (CD166) biomarkers in a cancer specimen obtained from the subject,
b) identifying the subject as one who is suitable for treatment with a methionine-cycle inhibitor when the expression levels of the biomarkers in the cancer specimen are increased as compared to the expression levels of the biomarkers in a non-cancerous specimen; and
c) administering a methionine cycle inhibitor to the subject when the subject is identified as one who is suitable for treatment with the methionine-cycle inhibitor, so as to treat cancer or reduce the risk of recurrence of cancer in the subject,
wherein the methionine-cycle inhibitor is a MAT2A inhibitor, D9, methotrexate or anti-folate.